Jason M. Uslaner, Ph.D. - Publications

Affiliations: 
2003 University of Michigan, Ann Arbor, Ann Arbor, MI 

56 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Vardigan JD, Lange HS, Tye SJ, Fox SV, Smith SM, Uslaner JM. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology. PMID 27117142 DOI: 10.1007/s00213-016-4290-1  1
2016 Stachel SJ, Zerbinatti C, Rudd MT, Cosden M, Suon S, Nanda KK, Wessner K, Dimuzio JM, Maxwell J, Wu Z, Uslaner JM, Michener MS, Szczerba P, Brnardic E, Rada V, et al. Identification and In Vivo Evaluation of Liver X Receptor β (LXRβ) Selective Agonists for the Potential Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry. PMID 27011007 DOI: 10.1021/acs.jmedchem.6b00176  1
2016 Pero JE, Rossi MA, Kelly MJ, Lehman HD, Layton ME, Garbaccio RM, O'Brien JA, Magliaro BC, Uslaner JM, Huszar SL, Fillgrove KL, Tang C, Kuo Y, Joyce LA, Sherer EC, et al. Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. Acs Medicinal Chemistry Letters. 7: 312-7. PMID 26985321 DOI: 10.1021/acsmedchemlett.5b00459  1
2016 Layton ME, Reif AJ, Hartingh TJ, Rodzinak K, Dudkin V, Wang C, Arrington K, Kelly MJ, Garbaccio RM, O'Brien JA, Magliaro BC, Uslaner JM, Huszar SL, Fillgrove KL, Tang C, et al. Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis. Bioorganic & Medicinal Chemistry Letters. PMID 26810316 DOI: 10.1016/j.bmcl.2016.01.021  1
2016 Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ. Inhibition of orexin signaling promotes sleep yet preserves salient arousability in monkeys Sleep. 39: 603-612. DOI: 10.5665/sleep.5536  1
2015 Raheem IT, Schreier JD, Fuerst J, Gantert L, Hostetler ED, Huszar S, Joshi A, Kandebo M, Kim SH, Li J, Ma B, McGaughey G, Sharma S, Shipe WD, Uslaner J, et al. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters. PMID 26602277 DOI: 10.1016/j.bmcl.2015.11.013  1
2015 Zhao F, Wang X, Zariwala HA, Uslaner JM, Houghton AK, Evelhoch JL, Williams DS, Winkelmann CT. fMRI study of olfaction in the olfactory bulb and high olfactory structures of rats: Insight into their roles in habituation. Neuroimage. PMID 26522425 DOI: 10.1016/j.neuroimage.2015.10.080  1
2015 Lange HS, Cannon CE, Drott JT, Kuduk SD, Uslaner JM. The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys. The Journal of Pharmacology and Experimental Therapeutics. 355: 442-50. PMID 26446308 DOI: 10.1124/jpet.115.226712  1
2015 Shipe WD, Sharik SS, Barrow JC, McGaughey GB, Theberge CR, Uslaner JM, Yan Y, Renger JJ, Smith SM, Coleman PJ, Cox CD. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. Journal of Medicinal Chemistry. PMID 26378882 DOI: 10.1021/acs.jmedchem.5b00983  1
2015 Gentzel RC, Toolan D, Roberts R, Koser AJ, Kandebo M, Hershey J, Renger JJ, Uslaner J, Smith SM. The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents. Neuropharmacology. PMID 26044638 DOI: 10.1016/j.neuropharm.2015.05.024  1
2015 Puri V, Wang X, Vardigan JD, Kuduk SD, Uslaner JM. The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model. Behavioural Brain Research. 287: 96-9. PMID 25800972 DOI: 10.1016/j.bbr.2015.03.029  1
2015 Vardigan JD, Cannon CE, Puri V, Dancho M, Koser A, Wittmann M, Kuduk SD, Renger JJ, Uslaner JM. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Psychopharmacology. 232: 1859-66. PMID 25491927 DOI: 10.1007/s00213-014-3813-x  1
2015 Chen A, Hines C, Dogdas B, Bone A, Lodge K, O'Malley S, Connolly B, Winkelmann CT, Bagchi A, Lubbers LS, Uslaner JM, Johnson C, Renger J, Zariwala HA. Targeting of deep-brain structures in nonhuman primates using MR and CT images Progress in Biomedical Optics and Imaging - Proceedings of Spie. 9415. DOI: 10.1117/12.2081620  1
2015 Uslaner JM, Renger JJ, Coleman PJ, Winrow CJ. A new class of hypnotic compounds for the treatment of insomnia: The dual orexin receptor antagonists Orexin and Sleep: Molecular, Functional and Clinical Aspects. 323-338. DOI: 10.1007/978-3-319-23078-8_17  1
2014 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. Bmc Neuroscience. 15: 109. PMID 25242351 DOI: 10.1186/1471-2202-15-109  1
2014 Kalinichev M, Le Poul E, Boléa C, Girard F, Campo B, Fonsi M, Royer-Urios I, Browne SE, Uslaner JM, Davis MJ, Raber J, Duvoisin R, Bate ST, Reynolds IJ, Poli S, et al. Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders. The Journal of Pharmacology and Experimental Therapeutics. 350: 495-505. PMID 24947466 DOI: 10.1124/jpet.114.214437  1
2014 Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV, Coleman P, Kuduk SD, Gotter AL, Marino M, Tye SJ, Uslaner JM, Winrow CJ, Renger JJ. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Frontiers in Behavioral Neuroscience. 8: 182. PMID 24904334 DOI: 10.3389/fnbeh.2014.00182  1
2014 Uslaner JM, Winrow CJ, Gotter AL, Roecker AJ, Coleman PJ, Hutson PH, Le AD, Renger JJ. Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement. Behavioural Brain Research. 269: 61-5. PMID 24746488 DOI: 10.1016/j.bbr.2014.04.012  1
2014 Eddins D, Hamill TG, Puri V, Cannon CE, Vivian JA, Sanabria-Bohórquez SM, Cook JJ, Morrow JA, Thomson F, Uslaner JM. The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. Psychopharmacology. 231: 511-9. PMID 24051602 DOI: 10.1007/s00213-013-3260-0  1
2014 Parmentier-Batteur S, Hutson PH, Menzel K, Uslaner JM, Mattson BA, O'Brien JA, Magliaro BC, Forest T, Stump CA, Tynebor RM, Anthony NJ, Tucker TJ, Zhang XF, Gomez R, Huszar SL, et al. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target. Neuropharmacology. 82: 161-73. PMID 23291536 DOI: 10.1016/j.neuropharm.2012.12.003  1
2013 Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, et al. Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Frontiers in Neuroscience. 7: 254. PMID 24399926 DOI: 10.3389/fnins.2013.00254  1
2013 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, ... ... Uslaner J, et al. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. Bmc Neuroscience. 14: 90. PMID 23981345 DOI: 10.1186/1471-2202-14-90  1
2013 Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, et al. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 2401-8. PMID 23722242 DOI: 10.1038/npp.2013.139  1
2013 Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, et al. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Science Translational Medicine. 5: 179ra44. PMID 23552372 DOI: 10.1126/scitranslmed.3005213  1
2013 Uslaner JM, Eddins D, Puri V, Cannon CE, Sutcliffe J, Chew CS, Pearson M, Vivian JA, Chang RK, Ray WJ, Kuduk SD, Wittmann M. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology. 225: 21-30. PMID 22825578 DOI: 10.1007/s00213-012-2788-8  1
2013 Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, Eddins D, Toolan DM, Kandebo M, Yao L, Raheem IT, Schreier JD, Breslin MJ, Coleman PJ, Renger JJ. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 64: 215-23. PMID 22750078 DOI: 10.1016/j.neuropharm.2012.06.013  1
2013 Cannon CE, Puri V, Vivian JA, Egbertson MS, Eddins D, Uslaner JM. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. Neuropharmacology. 64: 191-6. PMID 22659472 DOI: 10.1016/j.neuropharm.2012.05.003  1
2012 Raheem IT, Breslin MJ, Fandozzi C, Fuerst J, Hill N, Huszar S, Kandebo M, Kim SH, Ma B, McGaughey G, Renger JJ, Schreier JD, Sharma S, Smith S, Uslaner J, et al. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 22: 5903-8. PMID 22892116 DOI: 10.1016/j.bmcl.2012.07.072  1
2012 Bradley SR, Uslaner JM, Flick RB, Lee A, Groover KM, Hutson PH. The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling. Pharmacology, Biochemistry, and Behavior. 101: 35-40. PMID 22138407 DOI: 10.1016/j.pbb.2011.11.006  1
2012 Parmentier-Batteur S, O'Brien JA, Doran S, Nguyen SJ, Flick RB, Uslaner JM, Chen H, Finger EN, Williams TM, Jacobson MA, Hutson PH. Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration. Neuropharmacology. 62: 1453-60. PMID 21112344 DOI: 10.1016/j.neuropharm.2010.11.013  1
2012 Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Nguyen SJ, Surles NO, Yao L, Barrow JC, Uebele VN, Renger JJ, Clark J, Hutson PH. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology. 62: 1413-21. PMID 21110986 DOI: 10.1016/j.neuropharm.2010.11.015  1
2011 Vardigan JD, Converso A, Hutson PH, Uslaner JM. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. Journal of Neurogenetics. 25: 120-6. PMID 22070409 DOI: 10.3109/01677063.2011.630494  1
2011 Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE, Mullins D, Hyde LA, Eschle BK, Turnbull Z, Sloan H, Guzzi M, Zhang X, Wang A, Rindgen D, ... ... Uslaner JM, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology. 61: 665-76. PMID 21619887 DOI: 10.1016/j.neuropharm.2011.05.009  1
2011 Kalechstein A, Fantegrossi WE, Cowan RL, Mahoney JJ. Mdma Neuropsychology and Substance Use: State-of-the-Art and Future Directions. 171-206. DOI: 10.4324/9780203837719  1
2010 Garbaccio RM, Brnardic EJ, Fraley ME, Hartman GD, Hutson PH, O'Brien JA, Magliaro BC, Uslaner JM, Huszar SL, Fillgrove KL, Small JH, Tang C, Kuo Y, Jacobson MA. Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor. Acs Medicinal Chemistry Letters. 1: 406-10. PMID 24900224 DOI: 10.1021/ml100115a  1
2010 Smith SM, Uslaner JM, Hutson PH. The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors. The Open Medicinal Chemistry Journal. 4: 3-9. PMID 20648222 DOI: 10.2174/1874104501004020003  1
2010 Uslaner JM, Vardigan JD, Drott JM, Uebele VN, Renger JJ, Lee A, Li Z, Lê AD, Hutson PH. T-type calcium channel antagonism decreases motivation for nicotine and blocks nicotine- and cue-induced reinstatement for a response previously reinforced with nicotine. Biological Psychiatry. 68: 712-8. PMID 20579972 DOI: 10.1016/j.biopsych.2010.05.004  1
2010 Brnardic EJ, Fraley ME, Garbaccio RM, Layton ME, Sanders JM, Culberson C, Jacobson MA, Magliaro BC, Hutson PH, O'Brien JA, Huszar SL, Uslaner JM, Fillgrove KL, Tang C, Kuo Y, et al. 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. Bioorganic & Medicinal Chemistry Letters. 20: 3129-33. PMID 20409708 DOI: 10.1016/j.bmcl.2010.03.089  1
2010 Vardigan JD, Huszar SL, McNaughton CH, Hutson PH, Uslaner JM. MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacology, Biochemistry, and Behavior. 95: 223-9. PMID 20122952 DOI: 10.1016/j.pbb.2010.01.010  1
2010 Uslaner JM, Drott JT, Sharik SS, Theberge CR, Sur C, Zeng Z, Williams DL, Hutson PH. Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose. Behavioural Brain Research. 207: 37-43. PMID 19799936 DOI: 10.1016/j.bbr.2009.09.035  1
2010 Winrow CJ, Tanis KQ, Reiss DR, Rigby AM, Uslaner JM, Uebele VN, Doran SM, Fox SV, Garson SL, Gotter AL, Levine DM, Roecker AJ, Coleman PJ, Koblan KS, Renger JJ. Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology. 58: 185-94. PMID 19596018 DOI: 10.1016/j.neuropharm.2009.07.008  1
2009 Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Hutson PH. Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology. 206: 641-51. PMID 19707745 DOI: 10.1007/s00213-009-1644-y  1
2009 Uslaner JM, Parmentier-Batteur S, Flick RB, Surles NO, Lam JS, McNaughton CH, Jacobson MA, Hutson PH. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology. 57: 531-8. PMID 19627999 DOI: 10.1016/j.neuropharm.2009.07.022  1
2009 Smith SM, Uslaner JM, Yao L, Mullins CM, Surles NO, Huszar SL, McNaughton CH, Pascarella DM, Kandebo M, Hinchliffe RM, Sparey T, Brandon NJ, Jones B, Venkatraman S, Young MB, et al. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. The Journal of Pharmacology and Experimental Therapeutics. 328: 921-30. PMID 19088300 DOI: 10.1124/jpet.108.147884  1
2008 Uslaner JM, Dell'Orco JM, Pevzner A, Robinson TE. The influence of subthalamic nucleus lesions on sign-tracking to stimuli paired with food and drug rewards: facilitation of incentive salience attribution? Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 2352-61. PMID 18059435 DOI: 10.1038/sj.npp.1301653  1
2007 Jedynak JP, Uslaner JM, Esteban JA, Robinson TE. Methamphetamine-induced structural plasticity in the dorsal striatum. The European Journal of Neuroscience. 25: 847-53. PMID 17328779 DOI: 10.1111/j.1460-9568.2007.05316.x  1
2006 Uslaner JM, Robinson TE. Subthalamic nucleus lesions increase impulsive action and decrease impulsive choice - mediation by enhanced incentive motivation? The European Journal of Neuroscience. 24: 2345-54. PMID 17074055 DOI: 10.1111/j.1460-9568.2006.05117.x  1
2006 Uslaner JM, Acerbo MJ, Jones SA, Robinson TE. The attribution of incentive salience to a stimulus that signals an intravenous injection of cocaine. Behavioural Brain Research. 169: 320-4. PMID 16527365 DOI: 10.1016/j.bbr.2006.02.001  1
2005 Uslaner JM, Yang P, Robinson TE. Subthalamic nucleus lesions enhance the psychomotor-activating, incentive motivational, and neurobiological effects of cocaine. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 8407-15. PMID 16162923 DOI: 10.1523/JNEUROSCI.1910-05.2005  1
2003 Uslaner JM, Crombag HS, Ferguson SM, Robinson TE. Cocaine-induced psychomotor activity is associated with its ability to induce c-fos mRNA expression in the subthalamic nucleus: effects of dose and repeated treatment. The European Journal of Neuroscience. 17: 2180-6. PMID 12786985 DOI: 10.1046/j.1460-9568.2003.02638.x  1
2003 Uslaner JM, Norton CS, Watson SJ, Akil H, Robinson TE. Amphetamine-induced c-fos mRNA expression in the caudate-putamen and subthalamic nucleus: interactions between dose, environment, and neuronal phenotype. Journal of Neurochemistry. 85: 105-14. PMID 12641732  1
2001 Uslaner J, Badiani A, Day HE, Watson SJ, Akil H, Robinson TE. Environmental context modulates the ability of cocaine and amphetamine to induce c-fos mRNA expression in the neocortex, caudate nucleus, and nucleus accumbens. Brain Research. 920: 106-16. PMID 11716816 DOI: 10.1016/S0006-8993(01)03040-2  1
2001 Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Research. 102: 227-33. PMID 11440773 DOI: 10.1016/S0165-1781(01)00255-4  1
2001 Uslaner J, Badiani A, Norton CS, Day HE, Watson SJ, Akil H, Robinson TE. Amphetamine and cocaine induce different patterns of c-fos mRNA expression in the striatum and subthalamic nucleus depending on environmental context. The European Journal of Neuroscience. 13: 1977-83. PMID 11403691 DOI: 10.1046/j.0953-816X.2001.01574.x  1
2001 Day HE, Badiani A, Uslaner JM, Oates MM, Vittoz NM, Robinson TE, Watson SJ, Akil H. Environmental novelty differentially affects c-fos mRNA expression induced by amphetamine or cocaine in subregions of the bed nucleus of the stria terminalis and amygdala. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 732-40. PMID 11160452  1
1999 Uslaner J, Kalechstein A, Richter T, Ling W, Newton T. Association of depressive symptoms during abstinence with the subjective high produced by cocaine American Journal of Psychiatry. 156: 1444-1446. PMID 10484960  1
Show low-probability matches.